Browsing by Author "Zierhut, Manfred (57203252974)"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Epidemiology of Viral Induced Anterior Uveitis(2022) ;Radosavljevic, Aleksandra (56993158000) ;Agarwal, Mamta (20833248100) ;Chee, Soon Phaik (7005885793)Zierhut, Manfred (57203252974)Purpose: Viral agents are the most common cause of infectious anterior uveitis worldwide. The purpose of this review is to analyze the frequency, gender and racial differences of viral anterior uveitis (VAU) in various populations. Methods: Systematized literature review of epidemiological reports of VAU cited in PubMed, EMBASE and the Cochrane Library database published until June 30th, 2020. Results: A total of 12 clinical studies on epidemiology of definite VAU and 36 clinical studies of presumed VAU were identified. Members of Herpesviridae family represent the most common causes of VAU. Other less frequently reported causes, such as rubella and endemic viruses (HTLV-1, Chikungunya, Dengue, Ebola, Zika virus) were also analyzed. Conclusion: HSV, VZV are prevalent worldwide. CMV is more frequent in Asia, and rubella in the West. However, due to globalization and air travel, HTLV-1, Chikungunya, Dengue and Ebola may become important causes of VAU across the world. © 2020 Taylor & Francis Group, LLC. - Some of the metrics are blocked by yourconsent settings
Publication Medical Therapy of Uveitic Macular Edema: Biologic Agents(2020) ;Radosavljevic, Aleksandra (56993158000) ;Agarwal, Mamta (20833248100) ;Bodaghi, Bahram (56244598700) ;Smith, Justine R. (7410169450)Zierhut, Manfred (57203252974)Introduction: Uveitic macular edema (UME) is a significant cause of visual impairment in all uveitis types. Methods: Reports that were cited in the MEDLINE database, that analyzed the effectiveness of biologics for UME in at least five patients, with a minimum follow-up of 3 months, published prior to April 1, 2019 were included. Reports that did not compare UME findings before and after the therapy, using either OCT or fluorescein angiography, were excluded. Results: Case series that analyzed the efficacy of intravitreal anti-VEGF agents showed modest, short-term benefit. Studies that investigated systemic anti-TNF agents in patients with noninfectious uveitis reported a therapeutic effect on UME. Anti-IL-6 antibodies have shown promising results for most severe cases of noninfectious UME. Interferon represents an option for patients with persistent UME in infectious and noninfectious uveitis. Conclusion: Multicenter, randomized controlled trials are needed to assess the effectiveness of each group of biologic agents in sufficient number of patients. © 2020 Taylor & Francis Group, LLC. - Some of the metrics are blocked by yourconsent settings
Publication Systemic Lupus Erythematosus with Retinal Vasculitis(2021) ;Radosavljevic, Aleksandra (56993158000) ;Karadzic, Jelena (24767470400)Zierhut, Manfred (57203252974)A 36-year-old woman with systemic lupus erythematosus developed multiorgan involvement, including occlusive retinal vasculopathy and cystoid macular edema. Management of her ocular complications included combined laser photocoagulation, as well as immunomodulatory medication. © 2021 Elsevier Inc. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Tubulointerstitial Nephritis and Uveitis Syndrome (TINU)(2021) ;Zierhut, Manfred (57203252974) ;Radosavljevic, Aleksandra (56993158000)Karadzic, Jelena (24767470400)A 42-year-old female with past medical history of biopsy-proven interstitial nephritis that lasted for 2 years presented with bilateral anterior uveitis that lasted 5 months. The patient was treated with systemic and local corticosteroids and local mydriatics, after which the uveitis resolved. The patient was followed for 10 years in total and had three more attacks of mild anterior uveitis and cystoid macular edema that resolved after systemic corticosteroid and topical nonsteroidal antiinflammatory (NSAID) treatment. © 2021 Elsevier Inc. All rights reserved.
